Interaction between docetaxel resistance and castration resistance in prostate cancer: Implications of Twist1, YB-1, and androgen receptor

Prostate

Volumn 73, Issue 12, 2013, Pages 1336-1344

  Shiota, Masaki ^a   Kashiwagi, Eiji ^a   Yokomizo, Akira ^a   Takeuchi, Ario ^a   Dejima, Takashi ^a   Song, Yoohyun ^a   Tatsugami, Katsunori ^a   Inokuchi, Junichi ^a   Uchiumi, Takeshi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

androgen receptor; CRPC; docetaxel; Twist1; YB 1

Indexed keywords

ANDROGEN RECEPTOR; CYTOTOXIC AGENT; DOCETAXEL; HYDROGEN PEROXIDE; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ARTICLE; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANDROGEN RECEPTOR; CRPC; DOCETAXEL; TWIST1; YB-1;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NUCLEAR PROTEINS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TAXOIDS; TWIST TRANSCRIPTION FACTOR; Y-BOX-BINDING PROTEIN 1;

EID: 84881078552     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22681     Document Type: Article

References (30)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512.
2. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S,., Sartor AO, TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376 (9747): 1147-1154.
3. Fujimoto N, Shiota M, Kubo T, Matsumoto T,. Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer. Expert Rev Clin Pharmacol 2010; 3 (6): 785-795.
4. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X,. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65 (12): 5153-5162.
5. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K,. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009; 69 (7): 3148-3156.
6. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, Toi M, Fujii T, Yamana H, Kinoshita H, Kamura T, Tsuneyoshi M, Yasumoto K, Kohno K,. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004; 3 (11): 1485-1492.
7. Giménez-Bonafé P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, Gleave ME, Nelson CC,. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004; 59 (3): 337-349.
8. Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, Sorensen PH, Gleave ME,. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res 2011; 9 (12): 1755-1766.
9. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH,. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15 (5): 402-415.
10. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T, Naito S,. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010; 29 (2): 237-250.
11. Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y, Naito S,. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer 2011; 18 (4): 505-517.
12. Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, Tatsugami K, Uchiumi T, Oda Y, Naito S,. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol 2012; 187 (2): 707-714.
13. Wu CT, Chen WC, Liao SK, Hsu CL, Lee KD, Chen MF,. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocr Relat Cancer 2007; 14 (3): 633-643.
14. Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K, Naito S,. Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. J Urol 2012; 188 (1): 276-286.
15. Marin-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B,. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 2012; 11 (2): 329-339.
16. Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M,. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J Urol 2011; 185 (6): 2376-2381.
17. Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissière-Michot F, Maillé P, Kheuang L, Coppolani E, Ali A, Bibeau F, Culine S, Buttyan R, de la Taille A, Vacherot F,. Increased expression of class III β-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009; 101 (6): 951-956.
18. Hanssen L, Frye BC, Ostendorf T, Alidousty C, Djudjaj S, Boor P, Rauen T, Floege J, Mertens PR, Raffetseder U,. Y-box binding protein-1 mediates profibrotic effects of calcineurin inhibitors in the kidney. J Immunol 2011; 187 (1): 298-308.
19. Danciu TE, Whitman M,. Oxidative stress drives disulfide bond formation between basic helix-loop-helix transcription factors. J Cell Biochem 2010; 109 (2): 417-424.
20. Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C,. Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res 2012; 18 (10): 2964-2975.
21. Butler R, Leigh PN, Gallo JM,. Androgen-induced up-regulation of tubulin isoforms in neuroblastoma cells. J Neurochem 2001; 78 (4): 854-861.
22. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH,. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy. Prostate 2009; 69 (14): 1579-1585.
23. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N,. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010; 70 (20): 7992-8002.
24. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P,. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71 (18): 6019-6029.
25. Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H,. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69 (21): 8386-8394.
26. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME,. Timing is everything: Preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005; 11 (13): 4905-4911.
27. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME,. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008; 180 (2): 565-570.
28. Goodin S, Medina P, Capanna T, Shih WJ, Abraham S, Winnie J, Doyle-Lindrud S, Todd M, DiPaola RS,. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005; 23 (15): 3352-3357.
29. Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM,. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006; 24 (34): 5408-5413.
30. Amato RJ, Teh BS, Henary H, Khan M, Saxena S,. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urol Oncol 2009; 27 (2): 165-169.